Industry News

Biotechnology Industry News

Nykode Therapeutics has designed a…

August 27th, 2025|FierceBiotech|

Nykode Therapeutics has designed a two-year plan to turn its fortunes around. Having lost a deal with Genentech—and with the future of a Regeneron pact uncertain—the Norwegian biotech is focusing on delivering phase 2 data

Regeneron has reported a phase 3…

August 26th, 2025|FierceBiotech|

Regeneron has reported a phase 3 win in generalized myasthenia gravis, positioning the biotech to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular disease.

Novartis is putting down $30…

August 26th, 2025|FierceBiotech|

Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new drug in the neurodegeneration space.

Another cell therapy biotech has…

August 25th, 2025|FierceBiotech|

Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. California CAR-T company Appia Bio has closed up shop, founding CEO JeenJoo “JJ” Kang, Ph.D., wrote in an Aug.

Eli Lilly reported that all three…

August 25th, 2025|FierceBiotech|

Eli Lilly reported that all three doses of its oral GLP-1 orforglipron helped patients who are obese or overweight with Type 2 diabetes achieve “significant” weight loss in a phase 3 trial. The drug also

Akeso is adding a pair of…

August 25th, 2025|FierceBiotech|

Akeso is adding a pair of late-stage wins to its scorecard in both ankylosing spondylitis and atopic dermatitis, while also teeing up a new drug submission for one of the candidates.

After a nearly month-long delay,…

August 25th, 2025|FierceBiotech|

After a nearly month-long delay, the Food and Drug Administration has approved the investigational new drug application for Coya Therapeutics’ amyotrophic lateral sclerosis asset. With the FDA’s go-ahead, Coya plans to launch a multicenter phase

Arnatar Therapeutics has unveiled…

August 25th, 2025|FierceBiotech|

Arnatar Therapeutics has unveiled with $52 million in series A financing to bankroll new RNA-based therapies, including a lead candidate that takes aim at a rare genetic disease called Alagille syndrome.

AbbVie has written the next…

August 25th, 2025|FierceBiotech|

AbbVie has written the next chapter in its epic quest to treat psychiatric disorders, agreeing to buy a psychedelic drug candidate from Gilgamesh Pharmaceuticals for up to $1.2 billion.

PDS Biotech has reported final…

August 25th, 2025|FierceBiotech|

PDS Biotech has reported final phase 2 data on PDS0101 in head and neck cancer, linking a combination of the immunotherapy and Keytruda to median overall survival of 39.3 months.

The Supreme Court is allowing the…

August 22nd, 2025|FierceBiotech|

The Supreme Court is allowing the Trump administration to axe $783 million in federal research funding, reversing a lower court’s decision that required the National Institutes of Health to keep funding the terminated grants.

The Cleveland Clinic’s Nathan…

August 21st, 2025|FierceBiotech|

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology medical affairs at Bristol Myers Squibb.

The FDA’s recent rebuff of…

August 21st, 2025|FierceBiotech|

The FDA’s recent rebuff of Replimune’s melanoma candidate has rippled across the industry, prompting one biotech to shutter a clinical trial evaluating a similar drug.

The FDA has accepted Stealth…

August 21st, 2025|FierceBiotech|

The FDA has accepted Stealth BioTherapeutics’ third new drug application for its ultrarare disease candidate, providing a planned decision date of Sept. 26.